Trade Alert: Buying Catalysts, Selling A Rally
Two bullish healthcare trades and a bearish earnings trade tied to residential construction.
A Correction Splits The Opportunity Set
Corrections don’t make every falling stock a buy, and they don’t make every bounce sustainable. Our screens are separating names whose longer-term uptrends remain intact from names whose rebounds are failing inside broader downtrends.
That gives us three trades this morning: two bullish healthcare positions tied to identifiable catalysts, and one bearish earnings trade on a cyclical distributor. Both bullish candidates are above their 50-day exponential moving averages, and neither appears on our custom Bearish Rally Failure Chartmill screen. The bearish candidate remains below its declining 20-, 50-, and 200-day simple moving averages.
A Platform With Multiple Shots On Goal
Our first bullish candidate is a profitable gene-therapy platform with a commercial product that’s already scaling. This one comes to us from our Market Watchers X list. First-quarter global revenue rose 32%, gross margin was 95%, and the company ended the quarter with nearly $1 billion in cash, cash equivalents, and marketable securities.
Management has two registrational data readouts scheduled this year, while investors we follow see several additional second-half catalysts. The company reports Monday morning. There’s also speculation that a large pharmaceutical company could be circling (the flight tracker boys at it again), but we don’t need a takeover for the trade to work.
The obvious objection is event risk: earnings and clinical readouts can cut both ways, and the options reflect that. We’re answering it with a defined-risk combo entered for a credit, so we can make a modest profit on this if the stock goes sideways or even declines 10% or 15%, and we can more than double our money if it hits our target.
A Winner We Couldn’t Re-enter
Our second bullish candidate is a previous winner from our Multibaggers list that we tried to re-enter in Monday’s alert (as regular readers recall, our Multibaggers are a subset of our Market Watchers X List with multiple, recent 100%+ winners). That order didn’t fill, but the thesis hasn’t weakened. The stock finished Monday stronger, and its Chartmill Technical and Setup Ratings both improved to 8.
What changed is the geometry. We moved the call and put strikes higher to reflect the new share price, while tightening the maximum debit. The November long legs still span the company’s August and November earnings reports.
A Bounce Into Earnings, Not A Repaired Trend
Our bearish name is a national distributor tied to residential construction and repair-and-upgrade demand. First-quarter net sales were flat, and Organic Daily Sales fell 1% as roughly 3% price inflation masked lower volume. Management expects overall end-market demand to decline modestly in 2026.
The bullish counterargument is real: gross margin expanded 90 basis points and adjusted EBITDA rose 14% in the first quarter. The bearish case is that the operating improvement may not be enough if volume remains weak. The stock’s RSI has rebounded to 41, but its Chartmill Technical Rating is still 0, both its short- and long-term trends are down, and it reports Wednesday morning.
We’re deliberately using a shorter-dated structure here because this trade is partly an expression of the current correction. We don’t expect that correction to last as long as our usual trade structures do.
That’s why the structures differ. The catalyst-heavy platform uses a same-expiration credit combo. The former winner uses a hybrid that helps finance a November call with an October short call. The bearish earnings trade uses an inverted hybrid, selling an August put into elevated event volatility while preserving September downside exposure.
Full details are below, including the names and tickers, exact legs, entry limits, maximum gains and losses, and the pre-set exit orders we plan to place after any fills.
Today’s Market Watchers Trade
Commercial gene therapy / multiple-catalyst theme
RSI: 53; Chartmill Technical Rating: 9; Setup Rating: 6; Fundamental Rating: 6.
